American Heart Journal
Volume 156, Issue 2 , Pages 262-268 , August 2008

Impact of delayed presentation on management and outcome of non–ST-elevation acute coronary syndromes

  • Basem Elbarouni, MD

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Shaun G. Goodman, MD, MSc

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • Canadian Heart Research Centre, Toronto, Ontario, Canada
    • ,
  • Raymond T. Yan, MD

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Amparo Casanova, MD, PhD

      Affiliations

    • Canadian Heart Research Centre, Toronto, Ontario, Canada
    • ,
  • Abdul Al-Hesayen, MD

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Stephen Pearce, MD

      Affiliations

    • Surrey Memorial Hospital, Surrey, British Columbia, Canada
    • ,
  • David H. Fitchett, MD

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • Canadian Heart Research Centre, Toronto, Ontario, Canada
    • ,
  • Anatoly Langer, MD, MSc

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Andrew T. Yan, MD

      Affiliations

    • Terrence Donnelly Heart Centre, Division of Cardiology, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada
    • Canadian Heart Research Centre, Toronto, Ontario, Canada
    • Corresponding Author InformationReprint requests: Dr Andrew T. Yan, St. Michael's Hospital, Division of Cardiology, 30 Bond Street, Room 6-030 Queen, Toronto, Ontario, Canada M5B 1W8.
    • ,
  • for the Canadian ACS Registries Investigators

Received 4 December 2007 ,Accepted 21 March 2008.

References 

  1. Grossman SA, Brown DF, Chang Y, et al. Predictors of delay in presentation to the ED in patients with suspected acute coronary syndromes. Am J Emerg Med. 2003;21:425–428
  2. Rogers WJ, Canto JG, Lambrew CT, et al. Temporal trends in the treatment of over 1.5 million patients with myocardial infarction in the U.S. from 1990 through 1999: the National Registry of Myocardial Infarction 1, 2 and 3. J Am Coll Cardiol. 2000;36:2056–2063
  3. Goldberg RJ, Mooradd M, Gurwitz JH, et al. Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute myocardial infarction (the second National Registry of Myocardial Infarction). Am J Cardiol. 1998;82:259–264
  4. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Lancet. 1994;343:311–322
  5. Boersma E, Maas AC, Deckers JW, et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348:771–775
  6. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004;109:1223–1225
  7. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:E1–E211
  8. Goldberg RJ, Steg PG, Sadiq I, et al. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (the GRACE registry). Am J Cardiol. 2002;89:791–796
  9. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148–e304
  10. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non–Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Thrombolysis in Myocardial Ischemia. Circulation. 1994;89:1545–1556
  11. Bar FW, Verheugt FW, Col J, et al. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation. 1992;86:131–137
  12. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med. 1988;319:1105–1111
  13. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol. 1991;18:1587–1593
  14. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  15. Morrow DA, Antman EM, Snapinn SM, et al. An integrated clinical approach to predicting the benefit of tirofiban in non–ST elevation acute coronary syndromes. Application of the TIMI Risk Score for UA/NSTEMI in PRISM-PLUS. Eur Heart J. 2002;23:223–229
  16. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet. 2002;359:189–198
  17. Cohen M, Demers C, Gurfinkel EP, et al. Low-molecular-weight heparins in non–ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non–Q-wave coronary events. Am J Cardiol. 1998;82:19L–24L
  18. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non–Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999;100:1593–1601
  19. Granger CB, Goldberg RJ, Dabbous O, et al. In: Predictors of hospital mortality in the Global Registry of Acute Coronary Events. 2003;p. 2345–2353
  20. Roe MT, Peterson ED, Pollack CV, et al. Influence of timing of troponin elevation on clinical outcomes and use of evidence-based therapies for patients with non–ST-segment elevation acute coronary syndromes. Ann Emerg Med. 2005;45:355–362
  21. Miller CD, Banerjee A, Mahaffey KW, et al. Treatment and outcomes of patients with evolving myocardial infarction: experiences from the SYNERGY trial. Eur Heart J. 2007;28:1079–1084
  22. Newby LK, Christenson RH, Ohman EM, et al. Value of serial troponin T measures for early and late risk stratification in patients with acute coronary syndromes. The GUSTO-IIa Investigators. Circulation. 1998;98:1853–1859
  23. Yan AT, Tan M, Fitchett D, et al. One-year outcome of patients after acute coronary syndromes (from the Canadian Acute Coronary Syndromes Registry). Am J Cardiol. 2004;94:25–29
  24. Goldberg RJ, Gurwitz JH, Gore JM. Duration of, and temporal trends (1994-1997) in, prehospital delay in patients with acute myocardial infarction: the second National Registry of Myocardial Infarction. Arch Intern Med. 1999;159:2141–2147
  25. de Araujo Goncalves P, Ferreira J, Aguiar C, et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J. 2005;26:865–872
  26. Yan AT, Yan RT, Tan M, et al. Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better. Eur Heart J. 2007;28:1072–1078
  27. Yan AT, Jong P, Yan RT, et al. Clinical trial–derived risk model may not generalize to real-world patients with acute coronary syndrome. Am Heart J. 2004;148:1020–1027
  28. Kerensky RA, Wade M, Deedwania P, et al. Revisiting the culprit lesion in non–Q-wave myocardial infarction. Results from the VANQWISH trial angiographic core laboratory. J Am Coll Cardiol. 2002;39:1456–1463
  29. DeWood MA, Stifter WF, Simpson CS, et al. Coronary arteriographic findings soon after non–Q-wave myocardial infarction. N Engl J Med. 1986;315:417–423
  30. Keen WD, Savage MP, Fischman DL, et al. Comparison of coronary angiographic findings during the first six hours of non–Q-wave and Q-wave myocardial infarction. Am J Cardiol. 1994;74:324–328
  31. Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326:287–291
  32. Goldberg RJ, McGovern PG, Guggina T, et al. Prehospital delay in patients with acute coronary heart disease: concordance between patient interviews and medical records. Am Heart J. 1998;135(2 Pt 1):293–299
  33. Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation. 1999;99:1671–1677
  34. Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem. 2006;52:812–818
  35. Eggers KM, Oldgren J, Nordenskjold A, et al. Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction. Am Heart J. 2004;148:574–581
  36. Gaspoz JM, Unger PF, Urban P, et al. Impact of a public campaign on pre-hospital delay in patients reporting chest pain. Heart. 1996;76:150–155
  37. Herlitz J, Blohm M, Hartford M, et al. Follow-up of a 1-year media campaign on delay times and ambulance use in suspected acute myocardial infarction. Eur Heart J. 1992;13:171–177
  38. Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: the Rapid Early Action for Coronary Treatment (REACT) trial. JAMA. 2000;284:60–67

PII: S0002-8703(08)00278-0

doi: 10.1016/j.ahj.2008.03.025

American Heart Journal
Volume 156, Issue 2 , Pages 262-268 , August 2008

Article Tools

* Image Usage & Resolution